欢迎您加入月均活跃用户100万+的科研社区!如您有任何系统建议,请点此洽谈。
;如有合作推广需求,请近期推荐: | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 | 新 已发表SCI?是时候来Springer出书了! |
![]() |
基本信息 | 登录收藏 | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字![]() | Blood Advances BLOOD ADV (此期刊被最新的JCR期刊SCIE收录) LetPub评分 7.2
53人评分
我要评分
声誉 8.8 影响力 6.1 速度 7.0 | |||||||||||||||||||||
期刊ISSN | 2473-9529 | ![]() 蝌蝌APP,让您与同行交流更轻松
![]() | ||||||||||||||||||||
E-ISSN | 2473-9537 | |||||||||||||||||||||
2024-2025最新影响因子 (数据来源于搜索引擎) | 7.1 点击查看影响因子趋势图 | |||||||||||||||||||||
实时影响因子 | 截止2025年5月19日:7.085 | |||||||||||||||||||||
2024-2025自引率 | 4.20%点击查看自引率趋势图 | |||||||||||||||||||||
五年影响因子 | 7.1 | |||||||||||||||||||||
JCI期刊引文指标 | 1.87 | |||||||||||||||||||||
h-index | 暂无h-index数据 | |||||||||||||||||||||
CiteScore ( 2025年最新版) |
| |||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||
期刊官方网站 | https://www.journals.elsevier.com/blood-advances | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
期刊投稿网址 | ||||||||||||||||||||||
期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足Blood Advances的语言要求,还能让Blood Advances编辑和审稿人得到更好的审稿体验,让稿件最大限度地被Blood Advances编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
是否OA开放访问 | No | |||||||||||||||||||||
通讯方式 | 2021 L ST NW, SUITE 900, WASHINGTON, USA, DC, 20036 | |||||||||||||||||||||
出版商 | American Society of Hematology | |||||||||||||||||||||
涉及的研究方向 | Medicine-Hematology | |||||||||||||||||||||
出版国家或地区 | UNITED STATES | |||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||
出版周期 | ||||||||||||||||||||||
出版年份 | 0 | |||||||||||||||||||||
年文章数 | 492点击查看年文章数趋势图 | |||||||||||||||||||||
Gold OA文章占比 | 94.26% | |||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 96.14% | |||||||||||||||||||||
WOS期刊JCR分区 ( 2024-2025年最新版) | WOS分区等级:1区
| |||||||||||||||||||||
中国科学院《国际期刊预警 名单(试行)》名单 | 2025年03月发布的2025版:不在预警名单中 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||
中国科学院期刊分区 ( 2025年3月最新升级版) | 点击查看中国科学院期刊分区趋势图
| |||||||||||||||||||||
中国科学院期刊分区 ( 2023年12月升级版) |
| |||||||||||||||||||||
中国科学院期刊分区 ( 2022年12月旧的升级版) |
| |||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) 中科院的全球OA期刊索引(OAJ) | |||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2473-9529%5BISSN%5D | |||||||||||||||||||||
平均审稿速度 | 网友分享经验: | |||||||||||||||||||||
平均录用比例 | 网友分享经验: | |||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在Blood Advances顺利发表。
快看看作者怎么说吧:服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
期刊常用信息链接 |
|
|
|
中国学者近期发表的论文 | |
1. | Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study Author: Hu, Bei; Reagan, Patrick M.; Sehn, Laurie H.; Sharman, Jeff P.; Hertzberg, Mark; Zhang, Huilai; Kim, Austin; Herbaux, Charles; Molina, Lysiane; Maruyama, Dai; Stenner, Frank; Chohan, Saibah; Kothari, Rucha; Batlevi, Connie Lee; Hirata, Jamie; Sahin, Deniz; Lee, Calvin; Sugidono, Matthew; Tilly, Herve Journal: BLOOD ADVANCES. 2025; Vol. 9, Issue 10, pp. -. DOI: 10.1182/bloodadvances.2024014707 PubMed DOI |
2. | Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation Author: Politikos, Ioannis; Brown, Samantha; Fein, Joshua A.; Eng, Stephen; Casem, Kristian; Chinapen, Stephanie; Quach, Sean; Scaradavou, Andromachi; Cho, Christina; Dahi, Parastoo; Giralt, Sergio A.; Gyurkocza, Boglarka; Hanash, Alan M.; Jakubowski, Ann A.; Papadopoulos, Esperanza B.; Perales, Miguel-Angel; Ponce, Doris M.; Shaffer, Brian C.; Tamari, Roni; Young, James W.; Devlin, Sean; Peled, Jonathan U.; Barker, Juliet N Journal: BLOOD ADVANCES. 2025; Vol. 9, Issue 10, pp. 2570-2584. DOI: 10.1182/bloodadvances.2024014177 PubMed DOI |
3. | Metabolically aberrant extracellular mitochondria induce oxidative endotheliopathy in traumatic brain injury Author: Lu, Xiaoxi; Tang, Lujia; Wu, Yingang; Hilton, Tristan; Chen, Xin; Houck, Katie; Fulton, Sarah; Han, Cha; Romero, Sophia; Wang, Yi; Kozar, Rosemary; Cardenas, Jessica C.; Fu, Xiaoyun; Zhang, Jianning; Zhao, Zilong; Dong, Jing-fei Journal: BLOOD ADVANCES. 2025; Vol. 9, Issue 9, pp. 2079-2090. DOI: 10.1182/bloodadvances.2024015296 PubMed DOI |
4. | DNMT3A regulates murine megakaryocyte-biased hematopoietic stem cell fate decisions Author: Waldvogel, Sarah M.; Camacho, Virginia; Fan, Dandan; Guzman, Anna G.; Garcia-Martell, Alejandra; Khabusheva, Elmira; Pridgen, Jacey Rodriguez; de la Fuente, Josephine; Rau, Rachel; Laidman, Ashlyn G.; Barrachina, Maria N.; Carminita, Estelle; Courson, Justin A.; Williamson, Michael R.; Hsu, Joanne I.; Chen, Chun-Wei; Reyes, Jaime; Pradhan, Subhashree; Rumbaut, Rolando E.; Burns, Alan R.; Deneen, Benjamin; Su, Jianzhong; Machlus, Kellie R.; Goodell, Margaret A Journal: BLOOD ADVANCES. 2025; Vol. 9, Issue 9, pp. 2285-2299. DOI: 10.1182/bloodadvances.2024015061 PubMed DOI |
5. | Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies Author: Risitano, Antonio M.; de Castro, Carlos; Han, Bing; Kulasekararaj, Austin; Maciejewski, Jaroslaw P.; Scheinberg, Phillip; Ueda, Yasutaka; Vallow, Vallow; Bermann, Georgina; Dahlke, Marion; Kumar, Rakesh; de Latour, Regis Peffault Journal: BLOOD ADVANCES. 2025; Vol. 9, Issue 8, pp. 1816-1826. DOI: 10.1182/bloodadvances.2024014652 PubMed DOI |
6. | Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma Author: Liu, Jia; Zhang, Zilu; Xu, Wenbin; Jia, Mingyuan; Zeng, Xinyi; Wu, Chengyu; Fu, Ze; Xu, Xiaoguang; Ye, Chenjing; Wu, Chao; Xu, Hanzhang; Lei, Hu; Wu, Yingli; Yan, Hua Journal: BLOOD ADVANCES. 2025; Vol. 9, Issue 8, pp. 1991-2005. DOI: 10.1182/bloodadvances.2025015815 PubMed DOI |
7. | Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry Author: Pierson, Sheila K.; Brandstadter, Joshua D.; Torigian, Drew A.; Bagg, Adam; Lechowicz, Mary Jo; Alapat, Daisy; Casper, Corey; Chadburn, Amy; Chandrakasan, Shanmuganathan; Dispenzieri, Angela; Fossa, Alexander; Hoffmann, Christian; Ide, Makoto; Kurzrock, Razelle; Mukherjee, Sudipto; Nasta, Sunita; Navarro, Jose -Tomas; Noy, Ariela; Oksenhendler, Eric; Bustamante, Mateo Sarmiento; Shyamsundar, Saishravan; Streetly, Matthew; Wong, Raymond S. M.; Zhang, Lu; Lim, Megan S.; Srkalovic, Gordan; van Rhee, Frits; Fajgenbaum, David C Journal: BLOOD ADVANCES. 2025; Vol. 9, Issue 8, pp. 1952-1965. DOI: 10.1182/bloodadvances.2024014391 PubMed DOI |
8. | C3 as a predictive and prognostic biomarker in adult hemophagocytic lymphohistiocytosis: a large cohort study in China Author: Shu, Xuemei; Gao, Xinjie; Dai, Yujun; Wang, Yuxiang; Liu, Yilin; Wang, Dawei; Guo, Tao Journal: BLOOD ADVANCES. 2025; Vol. 9, Issue 8, pp. 1836-1846. DOI: 10.1182/bloodadvances.2024014715 PubMed DOI |
9. | Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study Author: Brown, Jennifer R.; Li, Jessica; Eichhorst, Barbara F.; Lamanna, Nicole; Brien, Susan M. O. '; Tam, Constantine S.; Qiu, Lugui; Huang, Ruiqi; Shi, Yang; Idoine, Adam; Salmi, Tommi; Cohen, Aileen Cleary; Shadman, Mazyar Journal: BLOOD ADVANCES. 2025; Vol. 9, Issue 8, pp. 1918-1926. DOI: 10.1182/bloodadvances.2024014206 PubMed DOI |
10. | Duration of primary/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis Author: Li, Anqi; Khatib, Rasha; Lopes, Luciane Cruz; Aloweni, Fazila; Lu, Liming; He, Qingyong; Wu, Jiaming; Zhang, Peiming; Tang, Yuyuan; Pavalagantharajah, Sureka; Sekercioglu, Nigar; Garcia, Carlos A. Cuello; Koujanian, Serge; Agarwal, Arnav; Kennedy, Sean Alexander; Neumann, Ignacio; Schulman, Sam; Wiercioch, Wojtek; Rada, Gabriel; Peseski, Andrew M.; Ortel, Thomas L.; Zhang, Yu-Qing Journal: BLOOD ADVANCES. 2025; Vol. 9, Issue 7, pp. 1742-1761. DOI: 10.1182/bloodadvances.2024015371 PubMed DOI |
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2025 中国: LetPub上海 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室